May 12 (UPI) — The Food and Drug Administration has granted approval for a novel medication to address the symptoms of menopause, specifically moderate to severe vasomotor symptoms, commonly referred to as “hot flashes.”
Introducing Veozah, an innovative non-hormonal treatment also known as fezolinetant. This groundbreaking medication revolves around the blocking of the neurokinin 3 receptor, an integral element in temperature regulation within the body. It has gained significant recognition as the first FDA-approved drug focusing on the inhibition of the NK3 receptor.
In its official statement, the FDA stated that Veozah should be taken orally, once a day, in the form of a 45 milligram pill. It can be taken with or without food, but it is crucial to maintain consistency by adhering to the same time each day.
While hormonal options for treating hot flashes are widely available, patients with a history of stroke, heart attack, vaginal bleeding, blood clots, or liver disease face safety concerns. Veozah, being non-hormonal, opens up opportunities for these patients who were previously unable to receive a suitable treatment.
The efficacy of Veozah was evaluated through randomized clinical trials, comparing its impact against placebos.
Prior to prescribing Veozah, patients should undergo bloodwork due to the potential risk of elevated hepatic transaminase, commonly referred to as liver injury. The FDA advises patients to contact their physician if they experience symptoms such as yellowing of the skin, vomiting, or nausea, which may indicate liver injury.
In terms of common side effects, diarrhea, back pain, insomnia, and abdominal pain are the most frequently reported with Veozah.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
